DigestRedComo funciona
Red
/
Empresas
F.
No verificado

F. Hoffmann-La Roche Ltd

Sobre qué escribimos

Anuncios brevesFarmacéuticaPublicidad/Marketing/Medios de comunicación/Comunicación

123 Comunicados de prensa

Ver todos los comunicados de prensa
23/03/2026
Farmacéutica
Anuncios breves
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
16/03/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
10/03/2026
Farmacéutica
Anuncios breves
Assemblée générale annuelle 2026 de Roche
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
10/03/2026
Farmacéutica
Anuncios breves
Roche Annual General Meeting 2026
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
08/03/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
06/03/2026
Farmacéutica
Anuncios breves
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
05/03/2026
Farmacéutica
Anuncios breves
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
01/03/2026
Farmacéutica
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
19/02/2026
Farmacéutica
Anuncios breves
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0
16/02/2026
Farmacéutica
Anuncios breves
Change to the Roche Enlarged Corporate Executive Committee
Fuente
F. Hoffmann-La Roche Ltd
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0